Free Trial

STAAR Surgical Q2 2024 Earnings Report

STAAR Surgical logo
$25.44 +1.51 (+6.31%)
(As of 12/17/2024 ET)

STAAR Surgical EPS Results

Actual EPS
$0.15
Consensus EPS
$0.24
Beat/Miss
Missed by -$0.09
One Year Ago EPS
$0.23

STAAR Surgical Revenue Results

Actual Revenue
$99.01 million
Expected Revenue
$95.22 million
Beat/Miss
Beat by +$3.79 million
YoY Revenue Growth
+7.30%

STAAR Surgical Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

STAAR Surgical Earnings Headlines

Analysts Set STAAR Surgical (NASDAQ:STAA) PT at $42.83
Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Staar Surgical price target lowered to $28 from $31 at Canaccord
Staar Surgical price target lowered to $23 from $27 at Morgan Stanley
Staar Surgical Co (STAA) Shares Down 3.45% on Dec 2
See More STAAR Surgical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like STAAR Surgical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on STAAR Surgical and other key companies, straight to your email.

About STAAR Surgical

STAAR Surgical (NASDAQ:STAA) Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

View STAAR Surgical Profile

More Earnings Resources from MarketBeat

Upcoming Earnings